Therapy Devices  Manufacturers, Traders, Suppliers

Company Profile – Sinocare Inc.
Sinocare Inc., founded in 2002 and headquartered in Changsha, China, is a high-tech medical company dedicated to the innovation and development of diabetes management and chronic disease monitoring solutions. The company focuses on providing professional, affordable, and user-friendly blood glucose monitoring systems and related healthcare products for people with diabetes and other chronic diseases worldwide.
Core Business & Products
Sinocare has established a comprehensive product portfolio covering:

• Blood Glucose Monitoring Systems (BGMs) and test strips
• HbA1c analyzers for long-term glycemic control assessment
• Multi-functional analyzers for lipids, uric acid, and other biomarkers
• Continuous Glucose Monitoring (CGM) systems
• Digital chronic disease management platforms integrating IoT and AI

Development & Strengths

• Listed Company: Went public in 2012 on the Shenzhen Stock Exchange GEM (Stock Code: 300298), becoming the first listed blood glucose meter company in China.
• R&D Capabilities: Owns a national-level technology center and a post-doctoral research station, with numerous patented core technologies in biosensors and rapid diagnostic testing.
• Global Expansion via Acquisitions: Acquired leading international companies such as PTS Diagnostics (USA) and Trividia Health (USA), enabling Sinocare to penetrate North American and global markets.
• Manufacturing Capacity: Operates advanced smart manufacturing facilities with an annual capacity of hundreds of millions of test strips and millions of glucose meters.

Market & Service

• Global Reach: Products are sold in over 135 countries and regions, serving more than 600 million people with diabetes and chronic diseases.
• China Market Leadership: Maintains a leading position in retail pharmacies, hospitals, and e-commerce platforms across China.
• International Market Presence: Rapidly expanding in North America, Europe, South America, and Asia through acquisitions, distribution networks, and strategic partnerships.

Vision & Mission
Sinocare’s mission is “To provide every person with diabetes with a blood glucose meter.”
Its long-term vision is to become a global leader in comprehensive chronic disease management solutions, leveraging digital healthcare, big data, and AI technologies to make chronic disease management simpler, smarter, and more effective.

Sinocare’s Technological Breakthroughs and Innovation Directions 1. Breakthrough in Second-Generation CGM (Continuous Glucose Monitoring System)
High-Precision Sensor Technology
The second-generation CGM adopts third-generation Direct Electron Transfer (DET) technology, which eliminates oxygen dependency, provides strong anti-interference capability, and ensures high accuracy. The MARD has been reduced to 8.71%, reaching international top-tier standards. Clinical data demonstrate that it can help lower HbA1c by 0.5–1% and reduce the incidence of severe hypoglycemia by over 50%.
Enhanced User Experience
The device features an all-in-one integrated design with a “one-press application” mechanism, requiring no manual assembly. With a thickness of less than 4 mm and a weight of approximately 2 g, it offers a comfortable and discreet wearing experience. The sensor supports daily activities such as showering and exercise, with a battery life of up to 15 days.
Regulatory Approvals and Global Expansion
In December 2024, Sinocare obtained the NMPA Class III registration certificate, and in July 2025, it received EU MDR certification. The product has already been registered and launched in multiple international markets, including Indonesia, the European Union, the United Kingdom, Thailand, and Malaysia, marking an important step in Sinocare’s global deployment.

Sinocare’s Current Technological Breakthroughs

• Development of new-generation biosensors with higher sensitivity and specificity, enabling more accurate blood glucose measurement.

Multi-Parameter Detection Technology

• Integration of multiple biomarkers (e.g., blood glucose, uric acid, blood lipids, HbA1c) into a single device, achieving comprehensive metabolic health monitoring.

Continuous Glucose Monitoring (CGM) Technology

• Progress in minimally invasive and wearable CGM systems, allowing real-time, continuous tracking of glucose fluctuations.

Microfluidics and Point-of-Care Testing (POCT)

• Utilization of microfluidic chips to reduce sample size and testing time, advancing rapid diagnostics at the point of care.

Artificial Intelligence (AI) & Big Data in Chronic Disease Management

• Application of AI algorithms and cloud platforms for intelligent data analysis, personalized health management, and remote patient monitoring.

Intelligent Connectivity & IoT Technology

• Development of smart blood glucose meters and chronic disease management devices with Bluetooth and cloud connectivity, enabling integration into digital healthcare ecosystems.

Next-Generation Test Strip Production Technology

• Improvement in automated, high-precision production lines to ensure consistent quality and large-scale supply of test strips.

High-Precision Sensing + Intelligent Multi-Correction AlgorithmThe company has successfully developed a “glucose sensing technology based on precise measurement and multi-correction algorithms”, which significantly enhances the accuracy and stability of blood glucose monitoring. By applying multiple algorithmic correction methods to optimize measurement results, this technology has received high recognition from experts during evaluation meetings and is regarded as reaching an internationally advanced level.Broad Industrial ApplicationThis technology has already been successfully industrialized and has become one of the core competitive strengths of Sinocare’s blood glucose monitoring products. With its wide adoption across domestic and international markets, supported by comprehensive quality certification systems, it plays a pivotal role in ensuring reliable, high-quality glucose monitoring solutions.